Eloisa Bonfá is full Professor of Rheumatology at Hospital das Clinicas HCFMUSP, São Paulo, which is the largest tertiary referral centre for autoimmune rheumatic disorders of Latin America. She is now in her third term elected Clinical Director of Hospital das Clinicas HCFMUSP, University of Sao Paulo.

Professor Bonfá’s main clinical and research interest is systemic lupus erythematosus and autoimmunity, with relevant contribution in the field of autoantibodies and original contribution regarding the association of anti-ribosomal P antibodies with psychiatric manifestation of lupus and the first “in vitro” demonstration of the arrhythmogenic potential of purified Ro/ SSA antibodies. She also has described the association of anti-ribosomal P antibodies and lupus membranous nephritis. She has published several papers on vaccine immunogenicity and safety in autoimmune disorders, including a large study with a COVID-19 vaccine. More recently, she has been dedicated to monitoring hydroxychloroquine blood levels in lupus patients.

Having graduated at the University of São Paulo Medical School, Brazil, Professor Bonfá undertook specialist training in Rheumatology in the same University followed by a 4 year rheumatology research fellowship at the Hospital for Special Surgery, New York, USA, under the supervision of Professor Keith Elkon. She has published more than 350 original papers indexed in PubMed and several book chapters.